Pre-Open Stock Movers 09/29: (AEGR) (ARWR) (EBAY) Higher; (ITCI) (ADHD) (FIT) Lower (more...)

September 29, 2016 8:52 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Today's After-Hours Movers

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) 63.2% LOWER; announced top-line results from the second Phase 3 clinical trial (Study 302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters and exhibited a safety profile similar to placebo. This replicates the safety and tolerability findings of a previous study (our Phase 2 Study 005) in which the efficacy of ITI-007 60 mg and risperidone, the active control, were similar.

Alcobra Ltd. (Nasdaq: ADHD) 59% LOWER; announced that it has received verbal notice from the Division of Psychiatry Products of the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on its Investigational New Drug (IND) applications for MDX in ADHD and Fragile X Syndrome. The clinical hold affects Alcobra’s ongoing Phase III clinical study of MDX in adult patients with ADHD, known as the “MEASURE” study.

Aegerion Pharma (NASDAQ: AEGR) 33% HIGHER; announced that Japans Ministry of Health, Labor & Welfare (MHLW) has approved JUXTAPID for patients with homozygous familial hypercholesterolemia (HoFH).

Arrowhead Pharmaceuticals Inc. (Nasdaq: ARWR) 19.1% HIGHER; Amgen (Nasdaq: AMGN) and Arrowhead Pharmaceuticals Inc. (Nasdaq: ARWR) announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowhead's proprietary subcutaneous RNAi delivery platform. RNAi molecules may be designed to target and shut down specific gene products that contribute to various diseases.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) 17% LOWER; announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25

REX Energy (NASDAQ: REXX) 9.9% HIGHER; Stifel upgraded from Sell to Hold.

Progress Software (NASDAQ: PRGS) 9.3% LOWER; reported Q3 EPS of $0.44, $0.01 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $102 million versus the consensus estimate of $104.72 million. GUIDANCE: Progress Software sees FY2016 EPS of $1.57-$1.60, versus the consensus of $1.61. Progress Software sees FY2016 revenue of $412-415 million, versus the consensus of $414.09 million. Progress Software sees Q4 2016 EPS of $0.55-$0.58, versus the consensus of $0.58. Progress Software sees Q4 2016 revenue of $123-126 million, versus the consensus of $122.65 million.

Bonanza Creek Energy (NYSE: BCEI) 8.6% HIGHER; Stifel upgraded from Sell to Hold with a price target of $1.00.

Fitbit (NYSE: FIT) 5.3% LOWER; Pacific Crest downgraded from Sector Weight to Underperform. MORE

TD Ameritrade (Nasdaq: AMTD) 4.3% HIGHER; is looking at Scottrade, according got media reports.

Nimble Storage (NYSE: NMBL) 3.6% HIGHER; Wells Fargo upgraded from Market Perform to Outperform with a price target of $10-$11 (from $9-$10). MORE

eBay (NASDAQ: EBAY) 3.2% HIGHER; Deutsche Bank upgraded from Hold to Buy with a price target of $40 (prior $30). More

Pier 1 Imports (NYSE: PIR) 3% HIGHER; reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $405.8 million versus the consensus estimate of $406.96 million. Company comparable sales for the quarter decreased 4.3%. GUIDANCE: Pier 1 Imports sees Q3 2017 EPS of $0.09-$0.15, versus the consensus of $0.12. Pier 1 Imports sees Q4 2017 EPS of $0.24-$0.32.

Globalstar, Inc. (NYSE: GSAT) 3% HIGHER; Company and its partner, ADS-B Technologies, announced the completion of the NASA Langley Research Center research flight with the Cirrus SR22 Unmanned Aerial System (UAS) Surrogate designed to test the operation of the ADS-B Link Augmentation System (ALAS). Initial results indicated continuous communication between the aircraft and Globalstars satellite system with only brief interruptions during extreme maneuvering, which reconnected quickly.

Pepsi (NYSE: PEP) 2.5% HIGHER; reported Q3 EPS of $1.40, $0.08 better than the analyst estimate of $1.32. Revenue for the quarter came in at $16 billion versus the consensus estimate of $15.83 billion. GUIDANCE: Pepsi sees FY2016 EPS of $4.78, versus the consensus of $4.76.

Himax Technologies (NASDAQ: HIMX) 1.8% HIGHER; Roth Capital initiated coverage with a Buy rating and a price target of $10.

ConAgra Foods (NYSE: CAG) 1.7% HIGHER; reported Q1 EPS of $0.61, $0.13 better than the analyst estimate of $0.48. Revenue for the quarter came in at $2.67 billion versus the consensus estimate of $2.73 billion.

Transocean (NYSE: RIG) 1.5% LOWER; Carl Icahn disclosed a 1.5%, or 5,477,900 share, stake in the company. This is down 74.50% from the 21,477,900 shares held at the end of the latest quarter ending June 30, 2016.

Apple (NASDAQ: AAPL) 0.6% LOWER; Barclays lowers numbers and removed as a Top Pick. MORE



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Carl Icahn, Stifel, Deutsche Bank, The Children's Investment Fund (TCI), Roth Capital, Barclays, Pacific Crest Securities, After-Hours Movers, Wells Fargo, Pre-Open Losers, Pre-Open Winners, Pre Market Movers

Add Your Comment